Bliss GVS Pharma Intrinsic Value
BLISSGVS • Healthcare
Current Stock Price
₹237.04
Primary Intrinsic Value
₹227.04
Market Cap
₹260.7 Cr
+100.0%
Upside
Median Value
₹474.08
Value Range
₹71 - ₹593
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
BLISSGVS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹227.04 | ₹181.63 - ₹272.45 | -4.2% | EPS: ₹10.32, Sector P/E: 22x |
| Book Value Method | asset | ₹592.60 | ₹533.34 - ₹651.86 | +150.0% | Book Value/Share: ₹992.73, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹474.08 | ₹426.67 - ₹521.49 | +100.0% | Revenue/Share: ₹920.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹474.08 | ₹426.67 - ₹521.49 | +100.0% | EBITDA: ₹208.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹592.60 | ₹474.08 - ₹711.12 | +150.0% | CF Growth: 13.4%, Discount: 15% |
| PEG Ratio Method | growth | ₹71.11 | ₹64.00 - ₹78.22 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹159.44 | ₹143.50 - ₹175.38 | -32.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹474.08 | ₹426.67 - ₹521.49 | +100.0% | ROE: 10.6%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹480.12 | ₹432.11 - ₹528.13 | +102.5% | EPS: ₹10.32, BVPS: ₹992.73 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
BLISSGVS Intrinsic Value Analysis
What is the intrinsic value of BLISSGVS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Bliss GVS Pharma (BLISSGVS) is ₹474.08 (median value). With the current market price of ₹237.04, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹71.11 to ₹592.60, indicating ₹71.11 - ₹592.60.
Is BLISSGVS undervalued or overvalued?
Based on our multi-method analysis, Bliss GVS Pharma (BLISSGVS) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 22.35 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 10.6% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.78x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Bliss GVS Pharma
Additional stock information and data for BLISSGVS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹106 Cr | ₹69 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹103 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹34 Cr | ₹31 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹136 Cr | ₹85 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹64 Cr | ₹42 Cr | Positive Free Cash Flow | 8/10 |